Research Article
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
Table 2
Impact of AR/ER, AR/PgR, and ER/PgR ratios on OS in primary tumors of luminal BC patients (no. 89).
| | Median ratios (range) |
| AR/ER | 0.95 (0.06 - 95.00) |
| AR/PgR | 1.55 (0.06 - 95.00) |
| ER/PgR | 1.60 (0.08 - 90.00) |
| OS according to best cut-off ratio | Median follow-up: 78 months (range 7 - 155) |
| | no. deaths/no. patients | Median OS (months) (95% CI) | HR (95% CI) | p |
| Overall | 55/89 | 63 (46-76) | - | - |
| AR/ER | | | | |
| <0.95 | 28/47 | 64 (41-82) | 1.00 | |
| ≥0.95 | 27/42 | 60 (42-83) | 1.05 (0.62-1.78) | 0.861 |
| AR/PgR | | | | |
| <1.54 | 21/39 | 82 (65-89) | 1.00 | |
| ≥1.54 | 34/50 | 42 (34-56) | 2.27 (1.30-3.97) | 0.004 |
| ER/PgR | | | | |
| <2.00 | 25/40 | 82 (62-88) | 1.00 | |
| ≥2.00 | 30/49 | 42 (34-64) | 1.89 (1.10-3.24) | 0.021 |
|
|
AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor; OS, overall survival; HR, hazard ratio; CI, confidence interval; ND, not determinable; NR, not reached.
|